

THE SENATE
THE THIRTIETH LEGISLATURE
REGULAR SESSION OF 2020

COMMITTEE ON COMMERCE, CONSUMER PROTECTION, AND HEALTH

Senator Rosalyn H. Baker, Chair
Senator Stanley Chang, Vice Chair

NOTICE OF DECISION MAKING

DATE: Tuesday, February 11, 2020
TIME: 10:15 AM
PLACE: Conference Room 229
State Capitol
415 South Beretania Street

A G E N D A

The following measures were previously heard on February 7, 2020. Due to a scheduling conflict, the decision making for these measures will be held at **10:15am** instead of the times announced by the Chair at the hearing:

<u>SB 3045</u> <u>Status & Testimony</u>	RELATING TO PRESCRIPTION DRUG RATE SETTING. Establishes a prescription affordability commission within the Department of Commerce and Consumer Affairs to review prescription drug costs and establish levels of reimbursement. Appropriates moneys.	CPH, WAM
<u>SB 2024</u> <u>Status & Testimony</u>	RELATING TO MEDICAL CANNABIS. Allows for a process to remediate any batch of cannabis that fails laboratory testing standards so long as any final product passes all such laboratory standards. Authorizes licensed retail dispensaries to sell edible cannabis products, under certain conditions, and circulate, sponsor, and promote educational and scientific information and events related to cannabis.	CPH, JDC
<u>SB 2280</u> <u>Status & Testimony</u>	RELATING TO PHARMACY BENEFIT MANAGERS. Prohibits pharmacy benefit managers from engaging in self-serving business practices. Replaces registration requirement with license requirement for pharmacy benefit managers. Increases pharmacy benefit manager reporting requirements to the insurance commissioner. Increases application and renewal fees and penalties for failure to renew a license.	CPH, JDC
<u>SB 2276</u> <u>Status & Testimony</u>	RELATING TO PRESCRIPTION DRUGS. Requires drug manufacturers to notify prescription drug benefit plans and pharmacy benefit managers if a proposed increase in the wholesale price of certain drugs would result in a sixteen per cent or more price increase over a two year period. Requires the drug manufacturer to identify and report to the insurance commissioner information on certain drugs whose wholesale acquisition cost increases by a certain amount during a specified time frame. Imposes fines.	CPH, JDC

SB 2278

[Status &
Testimony](#)

RELATING TO HEALTH INSURANCE.

CPH, JDC

Establishes disclosure and consent requirements for nonparticipating health care providers. Prohibits nonparticipating health care providers from balance billing patients in specific circumstances. Establishes rate calculation requirements for reimbursement of nonparticipating providers.

Decision making meeting only, no public testimony will be accepted.

FOR AMENDED NOTICES: Measures that have been deleted are stricken through and measures that have been added are underscored. If a measure is both underscored and stricken through, that measure has been deleted from the agenda.

If you require auxiliary aids or services to participate in the public hearing process (i.e. ASL or foreign language interpreter, or wheelchair accessibility), please contact the committee clerk at least 24 hours prior to the hearing so that arrangements can be made.

FOR FURTHER INFORMATION, PLEASE CALL THE COMMITTEE CLERK AT (808)586-6070.

Senator Rosalyn H. Baker
Chair